3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
25
Neoplasms
12
Prostatic Neoplasms
9
Multiple Myeloma
9
Neoplasm Metastasis
7
Giant Cell Tumor of Bone
7
Osteoporosis
4
Fractures, Bone
4
Recurrence
3
Kidney Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Bone Diseases, Metabolic
3
Bone Diseases
3
Spinal Cord Compression
2
Smoldering Multiple Myeloma
2
Parathyroid Neoplasms
2
Melanoma
2
Lymphoma
2
Lung Neoplasms
2
Bone Neoplasms
2
Bone Metastases
2
Bone Cysts, Aneurysmal
2
With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Thyroid Neoplasms
1
Thyroid Cancer Metastatic
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Interventions
Gemcitabine
679
130-nm albumin-bound paclitaxel
198
Fluorouracil
186
Oxaliplatin
175
Albumin-Bound Paclitaxel
151
Capecitabine
137
Leucovorin
131
Irinotecan
113
Radiotherapy
95
Taxes
83
pembrolizumab
80
Cisplatin
72
Erlotinib Hydrochloride
69
Radiosurgery
67
Nivolumab
56
Bevacizumab
54
Drug Therapy
52
Cyclophosphamide
49
Magnetic Resonance Spectroscopy
46
folfirinox
42
Docetaxel
41
Cetuximab
40
Specimen Handling
37
irinotecan sucrosofate
36
S 1 (combination)
36
Biopsy
31
Radiation
29
Paclitaxel
29
Ipilimumab
27
durvalumab
26
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Pancreatic Neoplasms
×
Denosumab
×
Clear all
NCT04907851
2025-03-17
KEYNOTE-E86
Redx Pharma Ltd
Phase 2
Completed
45 enrolled
25 charts